Catheter-Directed Thrombolysis for Acute Limb Ischemia

ABSTRACT

Acute limb ischemia is a potentially life-threatening clinical event. Thrombosis in situ, bypass graft thrombosis, and embolic occlusion are the three major precipitating events leading to acute limb ischemia. Management of acute ischemia depends on the clinical status of the affected limb and patient comorbidities. Catheter-directed thrombolysis (CDT) is the treatment of choice for patients with relatively mild acute limb ischemia (Rutherford categories I and IIa) with no contraindications to thrombolytic therapy. Patients with severe acute limb ischemia (Rutherford category IIb) need emergent revascularization. CDT should be considered, nonetheless, if the relative risks compared with primary operation are favorable. CDT is a life- and limb-saving treatment for many patients despite limitations of efficacy and associated complications. This article is a review of the etiology of acute arterial occlusion; clinical triage of patients presenting with acute limb ischemia; catheter guide wire techniques, pharmacological agents, and devices in current use for CDT; as well as the outcomes of CDT.

Thrombolysis - acute limb ischemia - plasminogen activator - anticoagulation

REFERENCES

• 1 Kasirajan K, Ouriel K. Management of acute lower extremity ischemia: treatment strategies and outcome.  Curr Interv Cardiol Rep. 2000;  2 119-129
• 2 Camerta A, White J V. Overview of catheter directed thrombolytic therapy for arterial and graft occlusion. In: Camerta A Thrombolytic Therapy for Peripheral Vascular Disease. Philadelphia; Lippincott-Ravenm 1995: 249-252
• 3 Dotter C T, Rosch J, Seaman A J. Selective clot lysis with low-dose streptokinase.  Radiology. 1974;  111 31-37
• 4 Kasirajan K, Haskal Z J, Ouriel K. The use of mechanical thrombectomy devices in the management of acute peripheral arterial occlusive disease.  J Vasc Interv Radiol. 2001;  12 405-411
• 5 Hirsch A T, Haskal Z J, Hertzer N R et al.. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). American College of Cardiology Web Site. Available at: http://www.acc.orglclinicaJ/guidelines/padlindex.pdf Accessed March 16, 2006
• 6 Makris M. Hyperhomocysteinemia and thrombosis.  Clin Lab Haematol. 2000;  22 133-143
• 7 Zipser S, Kirsch C M, Lien C et al.. Acute aortoiliac and femoral artery thrombosis complicating diabetic ketoacidosis.  J Vasc Interv Radiol. 2005;  16 1737-1739
• 8 Klinkert P, Post P N, Breslau P J et al.. Saphenous vein versus PTFE for above-knee femoropopliteal bypass: a review of the literature.  Eur J Vasc Endovasc Surg. 2004;  27 357-362
• 9 Sanchez L A, Suggs W D, Veith F J et al.. Is surveillance to detect failing polytetrafluoroethylene bypasses worthwhile? Twelve-year experience with ninety-one grafts.  J Vasc Surg. 1993;  18 981-989
• 10 Rutherford R B, Flanigan D P, Gupta S K et al.. Suggested standards for reports dealing with lower extremity ischaemia.  J Vasc Surg. 1986;  4 80-94
• 11 Blaisdell F W, Steele M, Allen R E. Management of acute lower extremity ischemia due to embolism and thrombosis.  Surgery. 1978;  84 822-834
• 12 Jivegard L, Holm J, Schersten T. The outcome of arterial embolism.  Acta Chir Scand. 1986;  152 251-256
• 13 Ouriel K, Shortell C K, De Weese J A et al.. A comparison of thrombolytic therapy with operative vascularization in the initial treatment of acute peripheral arterial ischemia.  J Vasc Surg. 1994;  19 1021-1070
• 14 The STILE Investigators . Results of a prospective randomised trial evaluating surgery versus thrombolysis for ischaemia of the lower extremity. The STILE trial.  Ann Surg. 1994;  220 251-268
• 15 Ouriel K, Veith F J, Sasahara A A. for the TOPAS Investigators . Thrombolysis or peripheral arterial surgery (TOPAS): phase I results.  J Vasc Surg. 1996;  23 64-75
• 16 Diffin D C, Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower-limb ischemia: a review of limb-salvage and mortality statistics.  J Vasc Interv Radiol. 1996;  7 57-63
• 17 Beyersdorf F, Matheis G, Kruger S et al.. Avoiding reperfusion injury after limb revascularization: experimental observations and recommendations for clinical application.  J Vasc Surg. 1989;  9 757-766
• 18 Working Party on Thrombolysis in the Management of Limb Ischemia . Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document.  J Vasc Interv Radiol. 2003;  14 S337-S349
• 19 Lonsdale R J, Berridge D C, Makin E S et al.. Role of echocardiography prior to peripheral arterial thrombolysis.  Br J Surg. 1990;  77 1429-1430 (Abstract)
• 20 Willmann J K, Baumert B, Schertler T et al.. Aortoiliac and lower extremity arteries assessed with 16-detector row CT angiography: prospective comparison with digital subtraction angiography.  Radiology. 2005;  236 1083-1093
• 21 Martin M L, Tay K H, Flak B et al.. Multidetector CT angiography of the aortoiliac system and lower extremities: a prospective comparison with digital subtraction angiography.  AJR Am J Roentgenol. 2003;  180 1085-1091
• 22 Quinn S F, Sheley R C, Semonsen K G et al.. Aortic and lower-extremity arterial disease: evaluation with MR angiography versus conventional angiography.  Radiology. 1998;  206 693-701
• 23 van Breda A, Katzen B T, Deutsch A S. Urokinase versus streptokinase in local thrombolysis.  Radiology. 1987;  165 109-111
• 24 Lonsdale R J, Berridge D C, Earnshaw J J et al.. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis.  Br J Surg. 1992;  79 272-275
• 25 Berridge D C, Gregson R H, Hopkinson B R et al.. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis.  Br J Surg. 1991;  78 988-995
• 26 Sugimoto K, Hofmann L V, Razavi M K et al.. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.  J Vasc Surg. 2003;  37 512-517
• 27 Razavi M K, Lee D S, Hofmann L V. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies.  J Vasc Interv Radiol. 2004;  15 13-23
• 28 Castaneda F, Swischuk J L, Li R et al.. Declining-dose study of reteplase treatment for lower extremity arterial occlusions.  J Vasc Interv Radiol. 2002;  13 1093-1098
• 29 Drescher P, Crain M R, Rilling W S. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.  J Vasc Interv Radiol. 2002;  13 37-43
• 30 Stewart R J, Fredenburgh J C, Leslie B A et al.. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.  J Biol Chem. 2000;  275 10112-10120
• 31 Hull J E, Hull M K, Urso J A et al.. Tenecteplase in acute lower-leg ischemia: efficacy, dose, and adverse events.  J Vasc Interv Radiol. 2006;  17 629-636
• 32 McNamara T O, Fischer J R. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase.  AJR Am J Roentgenol. 1985;  144 769-775
• 33 Ouriel K, Gray B, Clair D G et al.. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.  J Vasc Interv Radiol. 2000;  11 295-298
• 34 Semba C P, Bakal C W, Calis K A et al.. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.  J Vasc Interv Radiol. 2000;  11 279-287
• 35 Mehta R P, Johnson M S. Update on anticoagulant medications for the interventional radiologist.  J Vasc Interv Radiol. 2006;  17 597-612
• 36 Ouriel K, Castaneda F, McNamara T et al.. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.  J Vasc Interv Radiol. 2004;  15 229-238
• 37 Hull J E, Hull M K, Urso J A. Reteplase with or without Abciximab for peripheral arterial occlusions: efficacy and adverse events.  J Vasc Interv Radiol. 2004;  15 557-564
• 38 Davidian M M, Powell A, Benenati J F et al.. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions.  J Vasc Interv Radiol. 2000;  11 289-294
• 39 Duda S H, Tepe G, Luz O et al.. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone: a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.  Radiology. 2001;  221 689-696
• 40 Allie D E, Hebert C J, Lirtzman M D et al.. Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience.  J Endovasc Ther. 2004;  11 427-435
• 41 Clouse M E, Stokes K R, Perry L J et al.. Percutaneous intraarterial thrombolysis: analysis of factors affecting outcome.  J Vasc Interv Radiol. 1994;  5 93-100
• 42 Kessel D O, Berridge D C, Robertson I. Infusion techniques for peripheral arterial thrombolysis.  Cochrane Database Syst Rev. 2004;  (1) CD000985
• 43 Ward A S, Andaz S K, Bygrave S. Thrombolysis with tissue-plasminogen activator: results with a high-dose transthrombus technique.  J Vasc Surg. 1994;  19 503-508
• 44 Braithwaite B D, Buckenham T M, Galland R B et al.. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group.  Br J Surg. 1997;  84 646-650
• 45 Juhan C, Haupert S, Miltgen G et al.. A new intra arterial rt-PA dosage regimen in peripheral arterial occlusion: bolus followed by continuous infusion.  Thromb Haemost. 1991;  65 635
• 46 Kandarpa K, Chopra P S, Aruny J E et al.. Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion.  Radiology. 1993;  188 861-867
• 47 Valji K, Bookstein J J, Roberts A C et al.. Occluded peripheral arteries and bypass grafts: lytic stagnation as an end point for pulse-spray pharmacomechanical thrombolysis.  Radiology. 1993;  188 389-394
• 48 Semba C P, Murphy T P, Bakal C W et al.. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature.  J Vasc Interv Radiol. 2000;  11 149-161
• 49 Yusuf S W, Whitaker S C, Gregson R H et al.. Immediate and early follow-up results of pulse spray thrombolysis in patients with peripheral ischaemia.  Br J Surg. 1995;  82 338-340
• 50 Suenson E, Bjerrum P, Holm A et al.. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.  J Biol Chem. 1990;  265 22228-22237
• 51 Sakharov D V, Rijken D C. Superficial accumulation of plasminogen during plasma clot lysis.  Circulation. 1995;  92 1883-1890
• 52 McNamara T O, Bomberger R A. Factors affecting initial and six month patency rates after intra-arterial thrombolysis with high dose urokinase.  Am J Surg. 1986;  152 709-712
• 53 Gardiner Jr G A, Harrington D P, Koltun W, Whittemore A, Mannick J A, Levin D C. Salvage of occluded bypass grafts by means of thrombolysis.  J Vasc Surg. 1989;  9 426-431
• 54 Durham J D, Rutherford R B. Assessment of long-term efficacy of fibrinolytic therapy in the ischemic extremity.  Semin Intervent Radiol. 1992;  9 166-173
• 55 Sniderman K W, Bodner L, Saddekni S et al.. Percutaneous embolectomy by transcatheter aspiration. Work in progress.  Radiology. 1984;  150 357-361
• 56 Wagner H J, Starck E E. Acute embolic occlusions of the infrainguinal arteries: percutaneous aspiration embolectomy in 102 patients.  Radiology. 1992;  182 403-407
• 57 Lasic Z, Nikolsky E, Kesanakurthy S et al.. Vascular closure devices: a review of their use after invasive procedures.  Am J Cardiovasc Drugs. 2005;  5 185-200
• 58 Rajan D K, Patel N H, Valji K et al.. Quality improvement guidelines for percutaneous management of acute limb ischemia.  J Vasc Interv Radiol. 2005;  16 585-595
• 59 Schweizer J, Altmann E, Stosslein F et al.. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions.  Eur J Radiol. 1996;  22 129-132
• 60 Meyerovitz M F, Goldhaber S Z, Reagan K et al.. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.  Radiology. 1990;  175 75-78
• 61 Sugimoto K, Hofmann L V, Razavi M K et al.. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.  J Vasc Surg. 2003;  37 512-517
• 62 Cina C S, Goh R H, Chan J et al.. Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator.  Ann Vasc Surg. 1999;  13 571-575
• 63 Hanover T M, Kalbaugh C A, Gray B H et al.. Safety and efficacy of reteplase for the treatment of acute arterial occlusion: complexity of underlying lesion predicts outcome.  Ann Vasc Surg. 2005;  19 817-822
• 64 Mahmood A, Hardy R, Garnham A et al.. Microtibial embolectomy.  Eur J Vasc Endovasc Surg. 2003;  25 35-39